Pneumatosis Cystoides Intestinalis

Shindelman, Larry E.; Geller, Stephen A.; Wisch, Nathaniel; Bauer, Joel J.
April 1981
American Journal of Gastroenterology;Apr1981, Vol. 75 Issue 4, p270
Academic Journal
A case of pneumatosis cystoides intestinalis following administration of chemotherapy for Hodgkin s disease is presented. Because of a poor response to nonoperative management, a subtotal colectomy was performed. Although the pathogenesis of pneumatosis cystoides intestinalis is not entirely clear, it seems likely that, in this case, mucosal ulceration secondary to methyl-gag allowed intraluminal air to dissect into the intestinal wall and surrounding retro-peritoneal tissues. Because pneumatosis cystoides intestinalis is often reversible and self-limited, fecal diversion in lieu of bowel resection is entertained as a possible alternative in the operative management of selected cases. In the case presented resection was performed because of extent of the pathologic process.


Related Articles

  • Neoantigen Response in Patients Successfully Treated for Lymphoma. King, Gerald W.; Grozea, Petre C.; Eyre, Harmon J.; LoBuglio, Albert F. // Annals of Internal Medicine;Jun79, Vol. 90 Issue 6, p892 

    Assesses the cellular immune function of patients successfully treated for lymphoma by measuring skin-test reactivity to a battery of recall antigens, phytohemmagglutinin and dinitrochlorobenzene. Information on the case of patients with Hodgkin's disease and patients with non-Hodgkin's...

  • Erratum to: Standardized laparoscopic NOSE-colectomy is feasible with low morbidity. Wolthuis, Albert; Buck van Overstraeten, Anthony; Fieuws, Steffen; Boon, Katrien; D'Hoore, André // Surgical Endoscopy;May2015, Vol. 29 Issue 5, p1174 

    A correction to the article "Standardized laparoscopic NOSE-colectomy is feasible with low morbidity," by Albert M. Wolthius and colleagues published on the January 10, 2015 online issue is presented.

  • Malignant lymphomas. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;6/25/96, Vol. 9 Issue 6, p26 

    Presents updates related to malignant lymphomas. Classification of Hodgkin's disease; Non-Hodgkin's lymphomas; Therapeutic recommendations for Hodgkin's disease.

  • BEACOPP regimen associated with high rate of OS in high-risk Hodgkin's lymphoma.  // Hem/Onc Today;4/25/2011, Vol. 12 Issue 8, p3 

    The article reports on results of a study which showed the effectiveness of high-dose BEACOPP chemotherapy on children and adolescents who have high-risk Hodgkin's lymphoma.

  • Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma. Illidge, Tim; Ivanov, Andrei; Yong Du // Clinical Medicine: Therapeutics;2009, Issue 1, p621 

    B1 or Tositumomab was the first B-cell specific antibody to be discovered and it targets the CD20 antigen. The potential therapeutic importance of this discovery in targeting CD20, however remained unrealised until the mid 1990's when Tositumomab was radiolabelled and the 131I Tositumomab...

  • Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Elefante, Anjana; Czuczman, Myron S. // American Journal of Health-System Pharmacy;5/1/2010, Vol. 67 Issue 9, p713 

    Purpose. The pharmacology, efficacy, safety, and dosage and administration of bendamustine and its use in indolent non- Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are reviewed. Summary. Bendamustine is an alkylating agent that has a unique, multifaceted mechanism of action....

  • Guidelines recommended for treatment of early stages of Hodgkin's lymphoma. Brinson, Brandy // Hem/Onc Today;1/1/2008, Vol. 9 Issue 1, p36 

    The article discusses research being done on the effectiveness of the combination of chemotherapy and radiotherapy for treating patients with localized stage supradiaphragmatic Hodgkin's lymphoma. It references a study by Christophe Fermé et al, published in the "New England Journal of...

  • Salvage chemotherapy with alternating MINE–ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Fernández de Larrea, C.; Martínez, C.; Gaya, A.; López-Guillermo, A.; Rovira, M.; Fernández-Avilés, F.; Lozano, M.; Bosch, F.; Esteve, J.; Nomdedeu, B.; Montserrat, E.; Carreras, E. // Annals of Oncology;Jun2010, Vol. 21 Issue 6, p1211 

    Background: High-dose chemotherapy (HDT) followed by autologous stem-cell transplantation (ASCT) is considered the gold standard in the treatment of patients with relapsed or refractory Hodgkin’s lymphoma (HL). However, the optimal salvage regimen has not yet been established.

  • Effects of GnRH-a Co-Treatment Prior to Chemotherapy in Women with Hodgkin's disease.  // Fertility Weekly;3/16/2009, p5 

    The article presents a research from Egypt which determines the effects of luteinizing hormone releasing hormone (GnRH-a) co-treatment in women with Hodgkin's disease (HD) before chemotherapy. Research revealed that GnRH-a do not improve the ovarian reserve prior to chemotherapy. Moreover, it...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics